Shattering the underpinnings of neoplastic architecture in LNCaP: Synergistic potential of nutraceuticals in dampening PDGFR/EGFR signaling and cellular proliferation

Journal of Experimental Therapeutics and Oncology

Volumn 9, Issue 3, 2011, Pages 201-206

  Farooqi, Ammad Ahmad ^a   Bhatti, Shahzad ^a   Rana, Aamir ^a   Fayyaz, Sundas ^a   Mansoor, Qaisar ^b   Javed, Zeeshan ^a   Riaz, Asma M ^a   Nisar, Kinza ^a   Ahsan, Qurat Ul Ain ^a   Dilawar, Bilal Ahmed ^a   Asif, Hafiz ^a   Khanum, Reema ^a   Javeed, Mohammed Khalid ^a  

^a UNIVERSITY OF LAHORE   (Pakistan)

^b INSTITUTE OF BIOMEDICAL AND GENETIC ENGINEERING IBGE   (Pakistan)

Author keywords

Curcumin; EGCG; PDGFR; Prostate cancer; Sulforaphane

Indexed keywords

CURCUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; NUTRACEUTICAL; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SULFORAPHANE;

ARTICLE; CELL PROLIFERATION; CELL STRAIN LNCAP; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HORMONE SENSITIVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DRUG SYNERGISM; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; THIOCYANATES;

EID: 79959303943     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 398: 284-90, 2002. (Pubitemid 34848597)
2. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15: 197-204, 2004. (Pubitemid 38781045)
3. Li X, Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D Cytokine Growth Factor Rev 14: 91-8, 2003 Review. (Pubitemid 36389523)
4. Bowen-Pope DF, Hart CE, Seifert RA Sera and conditioned media contain different isoforms of platelet-derived growth factor (PDGF) which bind to different classes of PDGF receptor. J Biol Chem 264: 2502-8, 1989. (Pubitemid 19057737)
5. Seifert RA, Hart CE, Phillips PE, Forstrom JW, Ross R, Murray MJ, Bowen-Pope DF. Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. J Biol Chem 264: 8771-8, 1989. (Pubitemid 19151598)
6. Gronwald RG, Grant FJ, Haldeman BA, Hart CE, O'Hara PJ, Hagen FS, Ross R, Bowen-Pope DF, Murray MJ. Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: evidence for more than one receptor class. Proc Natl Acad Sci U S A 85: 3435-9, 1988.
7. Chen A, Zhang L. The antioxidant (-)-epigallocatechin-3-gallate inhibits rat hepatic stellate cell proliferation in vitro by blocking the tyrosine phosphorylation and reducing the gene expression of platelet-derived growth factor-beta receptor. J Biol Chem 278: 23381-9, 2003. (Pubitemid 36830154)
8. Yasuda Y, Shimizu M, Sakai H, Iwasa J, Kubota M, Adachi S, Osawa Y, Tsurumi H, Hara Y, Moriwaki H. (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R. Chem Biol Interact 182: 159-64, 2009.
9. Sakata R, Ueno T, Nakamura T, Sakamoto M, Torimura T, Sata M. Green tea polyphenol epigallocatechin-3-gallate inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J Hepatol 40: 52-9, 2004. (Pubitemid 38064713)
10. Weber AA, Neuhaus T, Skach RA, Hescheler J, Ahn HY, Schrör K, Ko Y, Sachinidis A. Mechanisms of the inhibitory effects of epigallocatechin-3 gallate on platelet-derived growth factor- BB-induced cell signaling and mitogenesis. FASEB J 18: 128-30, 2004.
11. Masamune A, Kikuta K, Satoh M, Suzuki N, Shimosegawa T. Green tea polyphenol epigallocatechin-3-gallate blocks PDGFinduced proliferation and migration of rat pancreatic stellate cells. World J Gastroenterol 11: 3368-74, 2005. (Pubitemid 40873241)
12. Takai S, Matsushima-Nishiwaki R, Adachi S, Natsume H, Minamitani C, Mizutani J, Otsuka T, Tokuda H, Kozawa O. (-)-Epigallocatechin gallate reduces platelet-derived growth factor-BB-stimulated interleukin-6 synthesis in osteoblasts: suppression of SAPK/JNK. Mediators Inflamm 2008: 291808, 2008.
13. Chadalapaka G, Jutooru I, Burghardt R, Safe S. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res 8: 739-50, 2010.
14. Patel BB, Gupta D, Elliott AA, Sengupta V, Yu Y, Majumdar AP. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res 30: 319-25, 2010.
15. Park SD, Jung JH, L ee HW, Kwon YM, Chung KH, Kim MG, Kim CH. Zedoariae rhizoma and curcumin inhibits plateletderived growth factor-induced proliferation of human hepatic myofibroblasts. Int Immunopharmacol 5: 555-69, 2005.
16. Lin J, Chen A. Activation of peroxisome proliferator-activated receptor-gamma by curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. Lab Invest 88: 529-40, 2008. (Pubitemid 351581455)
17. Zhao ZD, Huang ZS. Study on effects of curcumin on expressions of PDGF-BB, PDGFRbeta and ERK1 of HSC. Zhong Yao Cai 32: 732-5, 2009.
18. Choi HY, Lim JE, Hong JH. Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells. Prostate Cancer Prostatic Dis 13: 343-9, 2010.
19. Ide H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, Hama T, Masuda H, Horie S. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostatespecific antigen. Prostate 70: 1127-33, 2010.
20. Kim SH, Singh SV. D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells. Mol Cancer Ther 8: 1946-54, 2009.
21. Ustach CV, Taube ME, Hurst NJ Jr, Bhagat S, Bonfil RD, Cher ML, Schuger L, Kim HR. A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res 64: 1722-9, 2004. (Pubitemid 38428694)
22. Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J, Kim HR. A novel signaling axis of matriptase/ PDGF-D/b-PDGFR in human prostate cancer. Cancer Res 70: 9631-40, 2010.
23. Black PC, Brown GA, Dinney CP, Kassouf W, Inamoto T, Arora A, Gallagher D, Munsell MF, Bar-Eli M, McConkey DJ, Adam L. Receptor heterodimerization: a new mechanism for plateletderived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J Urol 185: 693-700, 2011.
24. Nazarova N, Golovko O, Bläuer M, Tuohimaa P. Calcitriol inhibits growth response to Platelet-Derived Growth Factor-BB in human prostate cells. J Steroid Biochem Mol Bio 94: 189-96, 2005. (Pubitemid 40614531)
25. Sachinidis A, Seul C, Seewald S, Ahn H, Ko Y, Vetter H. Green tea compounds inhibit tyrosine phosphorylation of PDGF betareceptor and transformation of A172 human glioblastoma. FEBS Lett 471: 51-5, 2000. (Pubitemid 30173291)
26. Sachinidis A, Skach RA, Seul C, Ko Y, Hescheler J, Ahn HY, Fingerle J. Inhibition of the PDGF beta-receptor tyrosine phosphorylation and its downstream intracellular signal transduction pathway in rat and human vascular smooth muscle cells by different catechins. FASEB J 16: 893-5, 2002.
27. Nair S, Barve A, Khor TO, Shen GX, Lin W, Chan JY, Cai L, Kong AN. Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3- gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells. Acta Pharmacol Sin 31: 1223-40, 2010.
28. Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, Moldenhauer G, Büchler MW, Salnikov AV, Herr I. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther 19: 188-95, 2011.
29. Kim SH, Singh SV. D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells. Mol Cancer Ther 8: 1946-54, 2009.
30. Hahm ER, Singh SV. Sulforaphane inhibits constitutive and interleukin-6-induced activation of signal transducer and activator of transcription 3 in prostate cancer cells. Cancer Prev Res (Phila) 3: 484-94, 2010.
31. Gibbs A, Schwartzman J, Deng V, Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A 106: 16663-8, 2009.
32. Andrzejewski T, Deeb D, Gao X, Danyluk A, Arbab AS, Dulchavsky SA, Gautam SC. Therapeutic efficacy of curcumin/ TRAIL combination regimen for hormone-refractory prostate cancer. Oncol Res 17: 257-67, 2008.
33. Shankar S, Ganapathy S, Srivastava RK. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res 14: 6855-66, 2008.